Australian Advantage
Why choose Australia & Crux Biolabs for your clinical studies?
Bespoke, reliable, timely & cost-effective contract immunology services. At Crux Biolabs, we take pride in becoming an extension of your team. We are 100% Australian-owned and located in Melbourne, the biotech capital of Australia.
The Australian
Advantage
- The Australian Regulatory Framework: CTN scheme 4-8 weeks for review, less than 12 weeks for study start-up
- No requirement for IND
- Melbourne, Victoria is a recognized leader in early-stage clinical trials, known for the quality of its clinical sites and the clinician expertise that facilitates the timely execution of excellent clinical trials
- Data generated at Crux Biolabs is ICH, FDA and EMA compliant and accepted for Phase 2 & 3 studies conducted globally
- Crux Biolabs is a registered Research Service Provider with the Australian Government. This allows easy claims for the full R&D Tax Incentive: 43.5% cash back for every $1 spent in R&D in Australia, available to international and local sponsors